[{"id":"a334d333-a3ba-49e5-a0c5-4e85464ed3d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470489","created_at":"2026-03-28T01:44:21.005Z","updated_at":"2026-03-28T01:44:21.005Z","phase":"Phase 2","brief_title":"A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial","source_id_and_acronym":"NCT07470489","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/30/2026","start_date":" 09/30/2026","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2026-03-13"},{"id":"95dd2ce0-ed59-4a61-b9b8-24f3c51885f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07020065","created_at":"2025-06-14T13:53:41.046Z","updated_at":"2025-06-14T13:53:41.046Z","phase":"Phase 2","brief_title":"Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 \u003c50%","source_id_and_acronym":"NCT07020065","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-13"},{"id":"f19011bc-a0f1-46bf-8979-e38379c2fbd2","acronym":"NEO-COMBATXL","url":"https://clinicaltrials.gov/study/NCT06902376","created_at":"2025-06-07T14:40:06.805Z","updated_at":"2025-06-07T14:40:06.805Z","phase":"Phase 1","brief_title":"XL092 and Cemiplimab in BRAF WT Thyroid Cancer","source_id_and_acronym":"NCT06902376 - NEO-COMBATXL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/03/2025","start_date":" 06/03/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-06-04"},{"id":"93ede10d-ac25-487a-8670-5b5938d492cb","acronym":"ARCH","url":"https://clinicaltrials.gov/study/NCT06931717","created_at":"2025-09-06T17:50:07.083Z","updated_at":"2025-09-06T17:50:07.083Z","phase":"Phase 3","brief_title":"A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy","source_id_and_acronym":"NCT06931717 - ARCH","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-05-11"},{"id":"3d25c448-acf8-4e6b-a932-342422e06f4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06908304","created_at":"2025-09-07T01:12:54.209Z","updated_at":"2025-09-07T01:12:54.209Z","phase":"Phase 3","brief_title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","source_id_and_acronym":"NCT06908304","lead_sponsor":"Maia Biotechnology","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • Libtayo (cemiplimab-rwlc) • vinorelbine tartrate • ateganosine (THIO)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/28/2025","start_date":" 07/28/2025","primary_txt":" Primary completion: 07/29/2026","primary_completion_date":" 07/29/2026","study_txt":" Completion: 07/29/2027","study_completion_date":" 07/29/2027","last_update_posted":"2025-04-08"},{"id":"e5a7e816-2338-4069-ab5a-d3e2d67f258f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04243616","created_at":"2021-01-18T20:37:50.114Z","updated_at":"2025-02-25T12:27:27.130Z","phase":"Phase 2","brief_title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","source_id_and_acronym":"NCT04243616","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PD-L1 • PGR • PD-L2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • PGR • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 07/14/2025","primary_completion_date":" 07/14/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-24"},{"id":"5b6f5e90-5c5a-4cbe-a9af-ed1c1a32c726","acronym":"","url":"https://clinicaltrials.gov/study/NCT04975152","created_at":"2021-07-23T13:52:34.008Z","updated_at":"2025-02-25T14:02:26.800Z","phase":"Phase 1","brief_title":"Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma","source_id_and_acronym":"NCT04975152","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"4d54d643-0fe9-4810-a13b-245e0370f07e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05840770","created_at":"2023-05-03T15:04:46.037Z","updated_at":"2025-02-25T14:09:39.987Z","phase":"Phase 2","brief_title":"Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 \u003e= 50% Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05840770","lead_sponsor":"City of Hope Medical Center","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 04/15/2025","start_date":" 04/15/2025","primary_txt":" Primary completion: 10/30/2029","primary_completion_date":" 10/30/2029","study_txt":" Completion: 10/30/2029","study_completion_date":" 10/30/2029","last_update_posted":"2025-02-18"},{"id":"71b6e7a1-e8f9-4246-9907-95c8f1bd4257","acronym":"","url":"https://clinicaltrials.gov/study/NCT06162572","created_at":"2023-12-08T19:16:46.816Z","updated_at":"2025-02-25T14:42:34.136Z","phase":"Phase 1/2","brief_title":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT06162572","lead_sponsor":"Servier Bio-Innovation LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • S95018 • S95029"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 08/07/2024","start_date":" 08/07/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-14"},{"id":"2a7ca647-6c30-4e9c-b1d6-666b4426ef4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05557591","created_at":"2022-09-28T17:01:05.693Z","updated_at":"2025-02-25T15:35:51.754Z","phase":"Phase 2","brief_title":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)","source_id_and_acronym":"NCT05557591","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • BNT116"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/21/2023","start_date":" 04/21/2023","primary_txt":" Primary completion: 03/02/2027","primary_completion_date":" 03/02/2027","study_txt":" Completion: 06/07/2027","study_completion_date":" 06/07/2027","last_update_posted":"2025-02-10"},{"id":"4b6f2c6e-35f3-4b56-9b34-2f31c986974d","acronym":"BNT111-01","url":"https://clinicaltrials.gov/study/NCT04526899","created_at":"2021-01-18T21:40:45.863Z","updated_at":"2025-02-25T15:26:32.109Z","phase":"Phase 2","brief_title":"Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma","source_id_and_acronym":"NCT04526899 - BNT111-01","lead_sponsor":"BioNTech SE","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • BNT111"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 01/25/2024","primary_completion_date":" 01/25/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-10"},{"id":"6875ca53-6d3a-4295-900b-d9b68a43e3c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04989946","created_at":"2023-12-21T18:18:35.344Z","updated_at":"2025-02-25T14:16:15.460Z","phase":"Phase 1/2","brief_title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","source_id_and_acronym":"NCT04989946","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Libtayo (cemiplimab-rwlc) • Firmagon (degarelix) • fianlimab (REGN3767) • MVI-118"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-07"},{"id":"c54aeb23-834a-4c49-9030-ec1b4fe12e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800015","created_at":"2023-04-05T14:03:34.879Z","updated_at":"2025-02-25T17:26:07.111Z","phase":"Phase 2/3","brief_title":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05800015","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)"],"overall_status":"Recruiting","enrollment":" Enrollment 950","initiation":"Initiation: 08/08/2023","start_date":" 08/08/2023","primary_txt":" Primary completion: 01/16/2030","primary_completion_date":" 01/16/2030","study_txt":" Completion: 12/23/2031","study_completion_date":" 12/23/2031","last_update_posted":"2025-01-31"},{"id":"2a191367-4b96-46b5-8c4d-764e4936a56d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06731270","created_at":"2025-02-25T18:59:30.448Z","updated_at":"2025-02-25T18:59:30.448Z","phase":"Phase 2","brief_title":"Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy","source_id_and_acronym":"NCT06731270","lead_sponsor":"Emory University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-01-23"},{"id":"a2aa78c5-6c40-4253-8db6-d0f14ce0af71","acronym":"","url":"https://clinicaltrials.gov/study/NCT06769698","created_at":"2025-02-26T07:08:07.434Z","updated_at":"2025-02-26T07:08:07.434Z","phase":"Phase 2","brief_title":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06769698","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/26/2025","start_date":" 03/26/2025","primary_txt":" Primary completion: 04/22/2027","primary_completion_date":" 04/22/2027","study_txt":" Completion: 11/28/2029","study_completion_date":" 11/28/2029","last_update_posted":"2025-01-10"},{"id":"0388c28a-65ca-445b-9f8d-078ae068c2a4","acronym":"THIO-101","url":"https://clinicaltrials.gov/study/NCT05208944","created_at":"2025-02-26T12:39:23.695Z","updated_at":"2025-02-26T12:39:23.695Z","phase":"Phase 2","brief_title":"THIO Sequenced with Cemiplimab in Advanced NSCLC","source_id_and_acronym":"NCT05208944 - THIO-101","lead_sponsor":"Maia Biotechnology","biomarkers":" IL6 • CRP","pipe":"","alterations":" ","tags":["IL6 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • ateganosine (THIO)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 06/08/2022","start_date":" 06/08/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-11-22"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"cbce4e03-be2e-4cae-8d0d-89ff40fa5446","acronym":"SiCARIO","url":"https://clinicaltrials.gov/study/NCT05501665","created_at":"2022-08-15T12:10:46.917Z","updated_at":"2025-02-25T16:26:59.959Z","phase":"Phase 1/2","brief_title":"Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer","source_id_and_acronym":"NCT05501665 - SiCARIO","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-10-17"},{"id":"8009476b-712f-4b6f-9467-7f222bfb4fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05450562","created_at":"2022-07-08T14:55:40.019Z","updated_at":"2024-07-02T16:35:00.176Z","phase":"Phase 1/2","brief_title":"Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05450562","lead_sponsor":"Sanofi","biomarkers":" ALK • GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["ALK • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • SAR444200"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 12/12/2030","primary_completion_date":" 12/12/2030","study_txt":" Completion: 12/12/2030","study_completion_date":" 12/12/2030","last_update_posted":"2024-05-30"},{"id":"865eb16a-cc7f-4591-a2db-0411186bb497","acronym":"R3767-ONC-2235","url":"https://clinicaltrials.gov/study/NCT05785767","created_at":"2023-03-27T20:03:40.832Z","updated_at":"2024-07-02T16:35:00.454Z","phase":"Phase 2/3","brief_title":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05785767 - R3767-ONC-2235","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)"],"overall_status":"Recruiting","enrollment":" Enrollment 850","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 03/11/2030","primary_completion_date":" 03/11/2030","study_txt":" Completion: 02/05/2032","study_completion_date":" 02/05/2032","last_update_posted":"2024-05-29"},{"id":"f52ea7ba-bfbd-4917-b198-17afffc30288","acronym":"","url":"https://clinicaltrials.gov/study/NCT05553834","created_at":"2022-09-23T17:07:20.162Z","updated_at":"2024-07-02T16:35:01.068Z","phase":"Phase 2","brief_title":"PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung","source_id_and_acronym":"NCT05553834","lead_sponsor":"Duke University","biomarkers":" EGFR • BRAF • MET • ROS1 • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Praluent (alirocumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2024-05-24"},{"id":"bec56339-c58d-4adf-b9c5-7c33103ad8b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05694871","created_at":"2023-01-23T14:59:43.962Z","updated_at":"2024-07-02T16:35:01.360Z","phase":"Phase 2","brief_title":"Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT05694871","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-L1 • RB1 • CDK4","pipe":" | ","alterations":" PD-L1 expression • RB1 mutation","tags":["PD-L1 • RB1 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-05-23"},{"id":"0bc35fbe-f69b-47e6-b74b-18c7493e9540","acronym":"","url":"https://clinicaltrials.gov/study/NCT05961709","created_at":"2023-07-27T18:09:11.074Z","updated_at":"2024-07-02T16:35:02.496Z","phase":"Phase 2","brief_title":"The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer","source_id_and_acronym":"NCT05961709","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/20/2024","start_date":" 05/20/2024","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-05-21"},{"id":"768a19ec-3d0c-41af-9664-7abdadcb116a","acronym":"EMPOWER-Lung 3","url":"https://clinicaltrials.gov/study/NCT03409614","created_at":"2021-01-18T16:49:19.466Z","updated_at":"2024-07-02T16:35:07.522Z","phase":"Phase 3","brief_title":"Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer","source_id_and_acronym":"NCT03409614 - EMPOWER-Lung 3","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Libtayo (cemiplimab-rwlc)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 790","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 02/03/2025","primary_completion_date":" 02/03/2025","study_txt":" Completion: 02/03/2025","study_completion_date":" 02/03/2025","last_update_posted":"2024-04-25"}]